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ABSTRACT: Cell-penetrating peptides (CPPs) have emerged as powerful tools in
terms of drug delivery. Those short, often cationic peptides are characterized by their
usually low toxicity and their ability to transport diverse cargos inside almost any kinds
of cells. Still, one major drawback is their nonselective uptake making their application
in targeted cancer therapies questionable. In this work, we aimed to combine the power
of a CPP (sC18) with an integrin-targeting unit (c[DKP-f 3-RGD]). The latter is
composed of the Arg-Gly-Asp peptide sequence cyclized via a diketopiperazine scaffold
and is characterized by its high selectivity toward integrin αvβ3. The two parts were
linked via copper-catalyzed alkyne−azide click reaction (CuAAC), while the CPP was
additionally functionalized with either a fluorescent dye or the anticancer drug
daunorubicin. Both functionalities allowed a careful biological evaluation of these novel
peptide-conjugates regarding their cellular uptake mechanism, as well as cytotoxicity in
αvβ3 integrin receptor expressing cells versus cells that do not express αvβ3. Our results
show that the uptake follows a “kiss-and-run”-like model, in which the conjugates first
target and recognize the receptor, but translocate mainly by CPP mediation. Thereby,
we observed significantly more pronounced toxic effects in αvβ3 expressing U87 cells
compared to HT-29 and MCF-7 cells, when the cells were exposed to the substances
with only very short contact times (15 min). All in all, we present new concepts for the
design of cancer selective peptide−drug conjugates.
■ INTRODUCTION
The deeper understanding of oncogenic molecular mechanisms
has provided new perspectives in the development of efficient
antitumor therapies. In the past few years, cancer research has
dramatically evolved, particularly with the advent of targeted
molecular therapies1−4 and advances in immunotherapy5−7 that
allowed the discovery and validation of innovative molecules,
more effective and less harmful than conventional chemo-
therapy. This fervor is demonstrated by several new FDA-
approved treatment strategies including immune check-point
inhibitors,8 adoptive T-cell therapy,9 and the approval of helpful
diagnostic tests to prognosticate the right targeted therapeutic to
each patient.10 As a consequence, the clinical practice guidelines
changed a lot over the past two decades. Despite all this progress,
cancer is still a leading cause of death worldwide.11 Indeed,
malignant cells often escape these treatments, or develop
resistance, so an improvement of the therapeutic index remains a
necessary goal.
One major obstacle of anticancer compounds is their inability
to cross body barriers, especially cell membranes. Cell
permeability of a drug has therefore been considered as a key
step for therapeutic efficacy. This need in successful drug
delivery has paved the way for the development of different drug
delivery strategies, including lipid- or peptide/protein-based
nanocarriers, inorganic vehicles, or other polymeric carriers.12 In
recent years, cell-penetrating peptides (CPPs) emerged as a
potent tool for intracellular delivery of bioactive compounds also
in the field of tumor diagnosis and therapy.13 CPPs are usually
short, cationic, and/or amphipathic peptides that are able to
autonomously transverse plasma membranes either by direct
permeation or via endocytotic processes, without the need for
auxiliary proteins such as transporters. In this context, promising
new CPP sequences have been identified and applied as vehicles
for bioactive molecules like oligonucleotides, peptides, metal−
organic complexes, and nanoparticles.14 One major drawback of
these peptides is their unselective uptake in nearly all cell types.
For this reason, endowing CPPs with cell-selectivity, especially
for future in vivo applications in cancer diagnosis or therapy, is a
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key factor in the development of these peptides. Recent progress
has beenmade by developing pH-responsive,15 ormaskedCPPs,
by making advantage of their cationic nature,16 or by fusion with
peptides that act as targeting units.17
Other targeted anticancer therapies include antibody−drug
conjugates (ADCs), which are specifically designed to act on
cancer cells with a selective, potent mechanism, targeting tumor
cells expressing surface antigens essential for their growth and
survival.18 Their antitumor efficacy and excellent tolerance
profile have allowed targeted molecular therapies to quickly
become therapeutic standards for many neoplastic conditions.19
However, often tumors develop mechanisms of resistance, and
the clinical benefit of these treatments remains limited over
time.20 In addition, ADCs have shown some important
limitations such as high unfavorable pharmacokinetics (low
tissue diffusion and low accumulation rate) and possible
immunogenicity with respect to targets located outside the
circulatory system and inside the cells, together with high
manufacturing costs and the need of a challenging chemical
synthesis.21 Therefore, small-molecule drug conjugates have
become of particular interest;22 among those, peptide−drug
conjugates were developed, that, in contrast to ADCs, are
characterized by a deep tissue penetration, the possibility of
targeting inside the cells, and relatively easy synthetic path-
ways.23
In the context of selectivity, integrins have received significant
attention as potential targets in cancer treatment.24 Integrins are
heterodimeric cell-transmembrane glycoproteins consisting of α
and β subunits. Depending on the combination of the different α
and β subunits, their ligand binding specificity, signaling
properties, and their affinity to endogenous proteins of the
extracellular matrix is determined. Integrins play major roles in
various cellular processes like cell adhesion, migration, and cell
proliferation even if the different biological functions of the
subtypes are only partially known. In particular, integrins αvβ3
are overexpressed on the surface of some tumor cells, influencing
themalignant potential of a tumor as well as host cell response to
cancer, being involved in tumor angiogenesis and meta-
stasis.25,26 These integrins recognize and bind the tripeptide
sequence RGD in their natural ligands, and several low
nanomolar peptidic ligands bearing this sequence have been
developed so far.27,28 Thanks to their excellent binding, RGD
integrin ligands have also been often used as very efficient
targeting units,29−31 although in some cases the ability of these
ligands to enhance efficient tumor penetration has been matter
of debate.27,32−36
In this work, we elucidated the concept of combining the
power of cell-penetrating peptides with the selectivity of an
integrin receptor ligand, with the aim to develop a peptide−drug
conjugate actively targeting tumor cells. In particular, the new
drug delivery system (DDS) is composed of a CPP, namely,
sC18,37 and an integrin ligand (c[DKP-RGD])38,39 charac-
terized by its high selectivity toward integrin αvβ3. For proof-of-
principle, the anticancer drug daunorubicin (dau) was used as
cytotoxic payload and covalently linked to the CPP by oxime
ligation. Daunorubicin is frequently applied as a toxin in cancer
treatment and research, and was thus used within this study.
Although it is characterized by high toxic potency, it lacks
selectivity, and therefore, safe and targeted delivery of this toxin
to the tumor cells would be preferable.40−42 The generated
products combine a highly selective homing device with the
merits of an efficient drug delivery vehicle (Figure 1).
■ RESULTS AND DISCUSSION
Synthesis of the Peptide−Drug Conjugates. Scheme 1
summarizes all CPP variants that were used to build up the
targeted DDS. The peptide sequence of sC18 was prepared by
automated SPPS, introducing at position 8 a lysine residue,
orthogonally protected as 1-(4,4-dimethyl-2,6-dioxocyclohex-1-
ylidene)ethyl derivative (Dde), to provide an attachment point
for 5(6)-carboxyfluorescein (CF), for cellular uptake studies,
and daunorubicin (dau), to obtain a drug-loaded peptide
conjugate. In addition, a N-terminal propargylglycine was
introduced, for subsequent chemical ligation to the integrin
ligand moiety via copper-catalyzed azide−alkyne click reaction
(CuAAC). This approach has been already adopted in our group
for the synthesis of triazole-containing cyclic peptides,43,44 and
the protocol used herein for CuAACwas recently established for
the preparation of RGD peptidomimetic−paclitaxel conju-
gates.45 Daunorubicin (dau) was conjugated to sC18 via oxime
ligation, using aminooxyacetic acid (Aoa) as linker.46 Oximes
and hydrazones have been used for the preparation of prodrugs
and conjugates of anthracyline drugs (such as daunorubicin and
doxorubicin) because they are normally stable at physiological
pH, while being rapidly cleaved at pH lower than 5.5, which is
encountered inside tumor cells.47 To facilitate the release of
Figure 1. Graphical model describing the setup of the new drug delivery system studied within this work.
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daunorubicin from theDDS further, we introduced theGly-Phe-
Leu-Gly sequence between the drug and the peptide carrier.
This sequence represents the recognition and cleavage site of
Cathepsin B, a lysosomal cysteine protease, which is highly
overexpressed in a wide variety of human cancers.48 The Gly-
Phe-Leu-Gly sequence was introduced between the drug and the
Scheme 1. (A) Exemplifies the Synthesis of the CPP Precursors That Were Differently Functionalized for Later Biological
Studiesa. (B) Highlights the Synthesis of Two Further Precursors (IV and V) That Were Used to Generate Compounds 3b and
3c, Respectivelyb
aa: 5 eqiv Fmoc-L-propargylglycine−OH (B), 5 equiv Oxyma, 5 equiv DIC in DMF, overnight; b: 30% piperidine in DMF (20 min × 2); c: 10
equiv Boc2O, 1 equiv DIPEA in DCM for 2 h (2×); d: 2% hydrazine in DMF (10×); e: 2 equiv CF, 2 equiv HATU, 2 equiv DIPEA in DMF for 2
h, then 5 equiv CF, 5 equiv Oxyma, 5 equiv DIC in DMF overnight; f: 20% piperidine in DMF, 45 min; g: 5 equiv Bis-Boc aminooxy acetic acid, 5
equiv Oxyma, 5 equiv DIC in DMF, overnight; h: TFA/TIS/H2O (95:2.5:2.5); i: 30% excess daunorubicin, 0.2 M NH4OAc, pH 5, 10 mg/mL; j:
acetone, rt, 30 min. bSee also Scheme 2 (B: propargylglycine; Aoa−OH: aminooxyacetic acid).
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peptide carrier as depicted in Schemes 1 and 2. Meanwhile,
c[DKP-RGD] was prepared as previously described and
functionalized with an azido PEG4-spacer.
49,50 Finally, all CPP
precursors where connected with the integrin targeting ligand by
CuAAC yielding the novel conjugates 1, 1a, 1b, and 1c (Scheme
2).
In addition to the drug conjugates containing both the CPP
and the integrin ligand, a series based on the CPP alone (2, 2a,
Scheme 2. Synthesis of the Full Conjugates 1, 1a, 1b, 1c, and 3b, 3ca
ak: 5 equiv TSTU, 5 equiv DIPEA, dry DMF, on; l: methoxylamine 1 M, NH4OAc 0.2 M, pH 5; i (see Scheme 1); m: PBS/MeCN, pH 7.3−7.5,
overnight; n: 0.5 equiv CuSO4·5H2O, 0.6 equiv Na ascorbate, H2O:DMF 1:1, 10 mM, 40 °C, N2, 24 h. (B: propargylglycine).
Table 1. List of All Synthesized Compounds with Their Names, Molecular Weights (MW), and IC50 Values
Code Conjugate MW [g/mol] MWexp [g/mol] IC50 [nM] αvβ3
a IC50 [μM] αvβ5
a
1 c[DKP-RGD]-sC18 2998.2 2998.3 16.7 ± 0.6 24.9 ± 2.7
1a c[DKP-RGD]-PEG4-sC18(Lys8-CF) 3355.9 3356.6 15.3 ± 5.2 2.5 ± 0.2
1b c[DKP-RGD]-PEG4-sC18(dau=Aoa-Lys8) 3580.1 3581.1 31.7 ± 4.2 >10
1c c[DKP-RGD]-PEG4-sC18(dau=Aoa-GFLG-Lys8) 3954.6 3955.6 9.7 ± 4.0 >10
2 sC18 2069.6 2069.9 n.d. n.d.
2a sC18(Lys8-CF) 2427.9 2428.9 n.d. n.d.
2b sC18(dau-Aoa-Lys8) 2652.2 2653.2 n.d. n.d.
3a c[DKP-RGD] 630.7 631.3 26.4 ± 3.7b >5b
3b c[DKP-RGD]-PEG4-Aoa=dau 1584.2 1585.0 14.0 ± 1.6 6.3 ± 0.4
3c dau=Aoa-GFLG-c[DKP-RGD] 1587.4 1587.9 5.8 ± 0.6 2.1 ± 0.1
aInhibition of biotinylated vitronectin binding to αvβ3 and αvβ5 receptors. IC50 values were calculated as the concentration of compound required
for 50% inhibition of biotinylated vitronectin binding as estimated by GraphPad Prism software; all values are the arithmetic mean SD of triplicate
determinations. bRef 50. n.d.: not determined.
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and 2b; refer to Table S1 for sequences), as well as the free
integrin ligand (3) and the drug-loaded c[DKP-RGD]
compounds 3b and 3c were also considered and prepared
(Schemes 1 and 2). All compounds were identified by mass
spectrometry and purified by preparative HPLC (Supporting
Information).
In Vitro Binding Assay on Isolated Integrin Receptors.
In a first instance, we measured the binding affinity of the new
conjugates to the isolated integrin receptors αvβ3 and αvβ5,
which are both tumor-associated integrins (Table 1). All
compounds tested were able to inhibit biotinylated vitronectin
binding to αvβ3 with low nanomolar affinity, indicating that the
presence of the CPP did not interfere with receptor targeting by
the integrin-targeting unit. 3a was already reported to be up to
200-fold more selective for αvβ3 with respect to αvβ5.
49,50
Interestingly, herein this selectivity was even more pronounced
for the conjugates 1 (up to 1500-fold), 1b (up to 330-fold), 1c
(up to 1000-fold), as well as conjugates 3b (up to 420-fold) and
3c (up to 340-fold).
Cellular Uptake of CF-Labeled Conjugates. For further
in vitro cell studies we used U87 glioblastoma, MCF-7 breast
cancer, and HT-29 colon carcinoma cells. For all of them, we
investigated the αvβ3 integrin expression by using flow
cytometry (Figure S1). U87 cells are reported to have an
enhanced expression of integrin αvβ3; on the contrary, HT-29
express αvβ5 but not αvβ3, and therefore they can be used as a
negative control.51 Our data confirmed these expression profiles
and did further reveal that also MCF-7 cells expressed αvβ3
receptors only to a minor amount, but anyway higher than HT-
29 cells.
The cellular uptake of the novel conjugates was then studied
in more detail, using the fluorescently labeled conjugates 1a and
2a, containing the integrin ligand and the CPP (1a) and only the
CPP (2a), respectively. Cells were incubated with the
Figure 2. (A)Cellular uptake in U87, HT-29, andMCF-7 cells as quantified by flow cytometry. Cells were incubated with 10 μMofCF-labeled peptide
solution for 30 and 60 min at 37 °C. ***: p < 0.001; **: p < 0.005 (unpaired t test). (B) Cellular uptake was analyzed by confocal laser scanning
microscopy. Cells were incubated for 30 min with 10 μM of CF-labeled peptide solution. Green: CF-labeled peptide; blue: Hoechst 33342 nuclear
stain; scale bar is 10 μm.
Figure 3. (A) Competition experiment: coincubation of the peptide (10 μM) with compound 3a, added in excess compared to 1a (10×). *: p > 0.5;
**: p < 0.01 (unpaired t test). (B) Blocking experiment: 30 min preincubation with 3a (10 μM) poly(L-lysine) or methyl-β-cyclodextrin (1 mM)
followed by 30 min incubation with a solution of 1a (10 μM). **: p < 0.02 (unpaired t test).
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compounds at 10 μMconcentration at two different time points:
30 and 60 min.
The internalization of 1a varied significantly over the
incubation time in all the three cell lines tested, while this effect
was not that obvious for sC18 itself. Interestingly, conjugate 1a
was taken up in U87 and HT-29 cells at nearly the same ratio,
while the uptake in MCF-7 cells was significantly lower.
Compared to this, conjugate 2a was internalized in U87 cells
much more than in HT-29 or MCF-7 cells. Moreover, the
uptake in U87 wasmuchmore intensive compared to 1a, leading
to the assumption that the internalization ability was somehow
altered by the addition of the targeting unit. An analysis of the
intracellular fate was done using confocal fluorescence
microscopy and supported the previously obtained data. Both
conjugates, 1a and 2a, were effectively internalized, but
displayed different intracellular distribution patterns: while in
HT-29 the compounds are initially entrapped in cytosolic
vesicles and then internalized into the nuclei, the distribution in
the other two cell lines showed the presence of the peptide
conjugates also within the cytoplasm (Figure 2B). All in all, we
did not observe any differences in the internalization pattern of
1a to 2a, and we were, thus, not able to define the impact of the
targeting unit on the entry pathway. To elucidate more precisely
this impact, and also, whether integrin receptor-mediated
endocytosis was involved, we performed more experiments
using U87 cells only.
First, the cellular uptake of 1a after 30 and 60 min
coincubation with the free ligand 3a was analyzed. The presence
of an excess (10-fold molar concentration) of the integrin ligand
was expected to compete with the integrin binding sites, thus
hampering the internalization of the conjugates. Notably, the
uptake of 1a was only slightly reduced when inspecting the cells
after 30 min (Figure 3A). However, this reduction seemed to
increase significantly after incubating the cells for a longer time
period. This would indicate a cellular uptake mediated by the
CPP part of the conjugate and only a minor influence of integrin
receptor-mediated endocytosis. We further investigated this
effect by blocking the cells by 30 min preincubation with free
ligand 3a, poly(L-lysine) (PLL) or methyl-β-cyclodextrin (mβ-
cd) (Figure 3B). Once again, blocking with 3a had only minor
influence, while PLL and mβ-cd significantly reduced the
cellular uptake. Poly(L-lysine) occupies all negatively charged
groups at the outer surface of the cell membrane, and thus,
disturbs CPP-mediated interaction with membrane constitu-
ents.52 Previously, we found out that the presence of cholesterol
is not that important for the cellular uptake of sC18 alone in
MCF-7 and HEK293 cells.15 Interestingly, this picture changed
for 1a, which is obviously dependent on the presence of
cholesterol, and whose cellular uptake significantly decreased
after incubating the cells first with mβ-cd. This might hint to a
different uptake pathway compared to the CPP alone. All in all,
we concluded that after interfering with the αvβ3 receptor, the
dual functional conjugate prefers CPP-mediated cellular
internalization.
Cytotoxicity of the Peptide−Drug Conjugates. In a next
step, the cytotoxic profiles of the dau-coupled conjugates (1b,
2b, 3b, 1c, 3c), as well as the control compounds 1 and 2, were
investigated. All cell lines, U87, HT-29, and MCF-7, were
Figure 4. Antiproliferative activity of the dau-conjugates, and 1, 2, as well as dau alone as controls in human U87, HT-29, and MCF-7 cells after 72 h
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incubated for 72 h with different concentrations of the
conjugates (Figure 4). Compound 1 showed minor toxicity
when applied at 100 μM to U87 and MCF-7 cells, in substantial
agreement with the observation that the targeting-unit alone can
induce cellular anoikis upon prolonged treatment.53 The free
peptide (2) significantly harmed U87 and MCF-7 cells at
concentrations of about 100 μM, thus confirming our
observation that sC18 can have an impact on cell viability of
cancer cells upon treatment with higher concentrations.16 Both
compounds, on the other hand, showed almost no influence on
cell viability when applied toHT-29 cells. These results probably
directly reflect the outcomes from the cellular uptake analysis,
and the observed higher cytotoxic effect against U87 cells is
directly proportional with the higher cellular uptake in this cell
line.
All dau-loaded conjugates showed high toxicity in all cell lines
tested with EC50 values in the lower micromolar range (Figure
4). These toxic effects are, however, definitely lower than the
nanomolar EC50 values shown by free drug daunorubicin, and
this effect is possibly due to the release of a daunorubicin
derivative, derived from proteolytic cleavage (dau=Aoa-Gly and
H-Lys), and of the free drug. Moreover, no clear selectivity trend
could be distinguished for the different conjugates among the
tested cell lines; compounds 3b and 3c, containing only the
integrin ligand, showed a moderate selective cytotoxic effect for
the integrin expressing cells U87, whereas for conjugate 2b
containing only the CPP, no selectivity at all was observed.
Figure 5. (A) Cellular uptake of the drug-loaded conjugates 1b−3b, 1c, and 3c in U87, HT-29, andMCF-7 cells as quantified by flow cytometry. Cells
were incubated with 10 μM of peptide solution for 15 min at 37 °C. *: p < 0.01; **: p < 0.001; ***: p < 2 × 10−5 (unpaired t test). (B) Confocal laser
scanning microscopy of U87, HT-29, and MCF-7 cells after incubating them for 30 min with 10 μM of peptide conjugate solutions. Red: dau
fluorescence; blue: Hoechst 33342 nuclear stain; scale bar is 10 μm.
Figure 6. Antiproliferative activity of conjugates 1b, 2b, 3b, 1c, and 3c in U87, HT-29, and MCF-7 cells. Cells were incubated for 15 min with peptide
solution, and then this solution was removed and cells were incubated for further 72 h. Values from the positive control (DMSO/EtOH; 1:1) were
subtracted from all data, and the untreated cells were set to 100%. Exemplary dose−response curves are shown fromwhich the effective concentrations
at which 50% of all cells were dead (EC50) were calculated.
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Overall, these results suggest a strong influence of the CPP
moiety in the internalization of the compounds, as already
observed in the uptake studies discussed above.
Investigating the Impact of Short Contact Times on
Cellular Uptake and Cytotoxicity. As a means to investigate
the possible role of the integrin ligand and the cell-penetrating
peptide in the targeting and internalization of our constructs, we
chose to incubate the cells for only a very short contact time with
the drug-loaded conjugates (15 min). In this manner, we aimed
at clarifying whether the establishment of a rapid binding of the
integrin targeting moiety to the surface receptor would help
increase the selectivity of the constructs, rather than the CPP-
driven unspecific uptake observed in the long incubation (72 h)
experiments. This procedure would also better simulate in vivo
conditions, in which the administered drug is assumedly rapidly
cleared from the tumor extracellular environment.
The cellular uptake of the dau-loaded conjugates was first
evaluated by flow cytometry after 15 min of incubation: all the
compounds were internalized, albeit to different extents (Figure
5A).
In particular, compounds 3b and 3c, possessing the integrin
targeting moiety and devoid of the CPP were internalized with
reduced efficiency: 3b was taken up in the lowest amounts
although with a significant preference for U87 compared to HT-
29 and MCF-7 cells, while 3c, containing the cathepsin B
cleavage sequence showed similar internalization and no
preference for any particular cell line. This observation confirms
the reduced internalization of integrin ligand drug conjugates
cited above. On the other hand, sC18-dau (2b), internalized
most in MCF-7, followed by U87 and HT-29. This internal-
ization ability is different than the one displayed by 2a, i.e., the
CF-labeled CPP, and this can be explained by the different
physicochemical properties of CF with respect to dau. A
significant preference for U87 cells was displayed by conjugate
1b, bearing the integrin targeting ligand and the CPP but not the
cathepsin cleavable linker. In this case, the internalization profile
matched the integrin expression found for the three cell lines.
Interestingly, this effect was reversed for 1c: in this case, the
uptake in U87 was lower compared to HT-29 and MCF-7 cells,
in which 1c internalized to very high extents. With these studies,
it became clear that the novel conjugates need only very short
contact times to internalize into the cells. Moreover, it seemed
that introducing a cathepsin B cleavage site led on one hand to
improved activity, but on the other hand lowered selectivity of
the conjugates.
Finally, we investigated how these short contact times would
impact cell viability of the different cell lines. Therefore, cells
were incubated with the compound solutions only for 15 min,
drained, and after addition of fresh cell culture media, cells were
incubated for further 72 h. As a general comment, the
cytotoxicity measured by this methodology parallels the
internalization ability of the same compounds, obtained with
the same 15 min incubation time. More specifically, compounds
1b and 3b demonstrated significantly higher activity against U87
cells compared to MCF-7 and HT-29 cells (Figure 6).
Importantly, 1b was more active than 3b demonstrating that
the attached CPP is indeed necessary to increase the overall
cellular uptake and thus cytotoxic activity of the conjugates. Of
note is also that 2bwas less efficient than 1b but marginally more
active than 3b, although with no selectivity. For the two
conjugates bearing the GFLG motif, it was seen that 3c is still
significantly more active in U87 cells expressing integrin
receptors. By contrast, 1c kept its selectivity against HT-29
cells, but was pronouncedly more active in MCF-7 cells
compared to 1b. This is presumably due to the reasons
discussed before, and mainly based on higher amounts of
cathepsin B in MCF-7 cells.
■ CONCLUSION
Summarizing, we present here for the first time peptide−drug
conjugates composed of a diketopiperazine-based integrin-
targeting unit and a cell-penetrating peptide. The synthesis is
very straightforward and allows incorporation of different active
groups, like the fluorescent dye CF, or the drug daunorubicin,
which were coupled to the CPP via a lysine side chain. We found
out that the cellular uptake follows a “kiss-and-run”-like model,
in which internalization is mediated mainly by the CPP part,
while the targeting unit helps to direct the conjugates selectively
to αvβ3 integrin-expressing cells. Based on only the short contact
times needed for selective targeting of integrin-expressing cells,
these novel PDCs are highly valuable and promising compounds
for the further development of anticancer drugs. Moreover, the
association of the targeting unit and the CPP proved to be a
necessary and powerful link that is worth studying inmore detail,
also by including other, possibly more cytotoxic, payloads. In the
future, we aim to use in vivo models for investigating the
selectivity of these novel PDCs against αvβ3 overexpressing
tumoral cells. Furthermore, the combination of these conjugates
with nanoparticle formulations could lead to the formation of
interesting multimodal drug delivery systems with tremendous
impact in this context. Recently, significant progress in this
direction has been demonstrated.31 Hopefully, with these
further studies, we will provide a new perspective on the
development of targeted CPP-based drug delivery systems.
■ EXPERIMENTAL SECTION
Material. Nα-Fmoc-protected amino acids, Oxyma Pure,
diisopropylcarbodiimide (DIC), trifluoroacetic acid, and 4-
(2′,4′-dimethoxyphenyl-Fmoc-aminomethyl)phenoxy (Rink
amide) resin were purchased from IRIS Biotech GmbH
(Marktredwitz, Germany). The following side chain protecting
groups were used: 2,2,4,6,7-pentamethyldihydrobenzofuran-5-
sulfonyl (Pbf) for Arg; Trityl (Trt) for Asn, His, and Gln; tert-
Butyl (tBu) for Asp and Glu; tert-butyloxycarbonyl (Boc) for
Lys. For the selective deprotection of side chains also Fmoc-
Lys(Dde)-OH was used. Unless otherwise stated, all reagents,
solvents, and consumables used were purchased from the
companies Alfa Aesar (Karlsruhe, Germany), Greiner Bio-One
(Kremsmünster, Austria), IRIS Biotech GmbH (Marktredwitz,
Germany), LP Italiana SPA (Milano, Italy), Merck (Darmstadt,
Germany), Roth (Karlsruhe, Germany), Ratiolab GmBH
(Dreieich, Germany), Sigma-Aldrich (Taufkirchen, Germany),
Sarstedt (Nümbrecht, Germany), and VWR BDH Prolabo
(Darmstadt, Germany), and their purity fulfilled at least the
specifications for synthesis quality. Daunorubicin hydrochloride
was a gift from Prof. Dr. Gab́or Mező (Budapest, Hungary).
Methods. Synthesis of the Drug-Free Conjugates. Peptides
were synthesized on Rink amide resin (100−200 mesh, loading:
0.48 mmol/g) by automated solid-phase peptide synthesis
(SPPS) on a multiple Syro II peptide synthesizer (Multi-
SynTech, Witten, Germany). Fmoc/tBu-strategy using a
double-coupling procedure and in situ activation with Oxyma/
DICwas used. Fmoc-Lys(Dde)−OH, propargylglycine, and 5,6-
carboxyfluorescein (CF) were coupled manually to the peptides
using 3 equiv of the reagent, 3 equiv Oxyma, and 3 equiv DIC for
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2 h or overnight; the procedure was repeated twice. The success
of the coupling was then controlled by Kaiser test. For the
labeling with CF theN-terminus was protected with a Boc group
by a reaction with 10 equiv di-tert-butyl-dicarbonate and 1 equiv
DIPEA in DCM for 2 h. After that, Dde cleavage was performed
with a solution of 3% hydrazine in DMF (12 × 10 min). The
peptide was finally cleaved from the resin using TFA:water:TIS
(95:2.5:2.5, v/v/v). After 3 h reaction at room temperature, the
peptides were precipitated in ice cold diethyl ether and then
washed and centrifuged 5 times at 4 °C, 5000 rpm; the pellet was
lyophilized from water:tert-butyl alcohol (3:1 v/v) and analyzed
by RP-HPLC-ESI-MS on a Chromolith Performance RP-18e
column, 100 × 4.6 mm fromMerck (Darmstadt, Germany), and
using linear gradients of 10−60% B in A (A = 0.1% FA in water;
B = 0.1% FA in acetonitrile) over 15 min and a flow rate of 0.6
mL min−1. Further purification of the peptides was achieved by
preparative HPLC, Hitachi Elite LaChrom (VWR, Darmstadt,
Germany) on RP18 column Nucleodur C18ec, 100−5 from
Macherey-Nagel (Düren, Germany) at 6 mL min−1 and 220 nm
detection. Acetonitrile/water with 0.1% TFA were used as
eluents, changing gradient as needed. The collected fractions
were evaporated, analyzed with LC-MS, and lyophilized to
obtain the purified peptides with purities >95%.
Coupling of the Peptide to the c[DKP-RGD]-PEG4-N3. The
c[DKP-RGD]-PEG4-N3 was conjugated to the peptide con-
jugate by a copper(I) catalyzed azide−alkyne cycloaddition
(click reaction) occurring between the azido group of the PEG
linker and the alkyne group of the propargylglycine. 1.3 equiv of
the azido compound was dissolved with 1 equiv of the alkyne-
containing peptide in dry DMF/degassed water 1:1 in a Schlenk
tube under nitrogen atmosphere reaching a concentration of 10
mM. Stock solutions of CuSO4 and Na ascorbate in degassed
water were prepared and 0.5 equiv and 0.6 equiv, respectively,
were added to the reaction. The solution was stirred overnight
under nitrogen atmosphere at 40 °C. The reaction was followed
by LC-MS to completion and then directly injected into the
HPLC on a semipreparative RP18 column for purification
obtaining final conjugates with purities >95%.
Synthesis of the Drug Conjugates Containing the CPP
Moiety. The synthesis of the peptide followed the same
procedure as previously described. For the attachment of the
daunorubicin to the peptide by an oxyme bond, a molecule of
Bis-Boc aminooxyacetic acid was coupled to the side chain of a
lysine (3 equiv with oxyma and DIC overnight). The success of
the coupling was checked by Kaiser test. The cleavage from the
resin occurred with the standard scavenger, but, as already
described by Mezö et al.,54 10 equiv of Boc-aminooxyacetic acid
was added in the cleavage cocktail in order to avoid the
formation of the aceton adduct with mass +40. After
precipitation, washing, and purification, the peptide was
dissolved in ammonium acetate buffer 0.2 M at pH 5 reaching
a concentration of 10 mg peptide/mL for the coupling to the
drug. Daunorubicin was added in excess of about 30% and the
reaction was stirred overnight. In order to remove excess of
daunorubicin, the reaction solution was directly injected into the
HPLC on a semipreparative RP18 column Nucleodur C18ec,
100−5 from Macherey-Nagel (Düren, Germany) at 1.5 mL
min−1 and 220 nm detection. Acetonitrile/water with 0.1% TFA
were used as eluents, changing gradient as needed. The collected
fractions were evaporated, analyzed with LC-MS, and
lyophilized to obtain the purified peptides with purities >95%.
Synthesis of Compound 3b. Rink amide resin (144 μmol
scale) was manually loaded with the Fmoc-propargylglycine−
OH(oxyma, DIC, overnight andHATU,DIPEA for 2 h). After a
capping procedure to block the unreacted groups on the resin
(acetic anhydride and DIPEA in DMF), Fmoc deprotection of
the amino acid with 30% solution of piperidine in DMF was
performed. Bis-Boc-Aminooxyacetic acid was then manually
coupled twice (Oxyma, DIC in DMF for 2 h). Full cleavage of
the peptide from the resin was performed using TFA:TIS:water
(90:2.5:2.5, v/v/v) in the presence of 5 equiv Boc-Aoa−OH.
The dipeptide was precipitated in ice cold diethyl ether/hexane
1:3 and then washed, lyophilized, and purified. Further steps
followed the same strategy as previously described.
Synthesis of 3c.TheGLFG tetrapeptide was synthesized on a
2-chlorotrityl chloride resin (H-Gly-2CT Resin, 100−200 mesh,
0.87 mmol/g, 0.015 mmol scale) by automated multiple solid-
phase peptide synthesis (Fmoc strategy). Bis-Boc-Aminooxy-
acetic acid was coupled manually. After cleavage from the resin,
the peptide was purified byHPLC and then stirred in acetone for
30 min at room temperature to protect the aminooxy group with
an isopropylidene group. c[DKP-RGD] was then coupled to the
C-terminus of the peptide using TSTU and DIPEA (both 5
equiv) in dry DMF (20 mM). The reaction was incubated
overnight and then directly purified by HPLC. The
isopropylidene group was then cleaved from the Aoa dissolving
the peptide in 1 M CH3ONH2·HCl (methoxylamine hydro-
chloride) containingNH4OAc-buffer (0.2M, pH 5) (20 equiv at
least). The reaction mixture was then directly purified by
semipreparative HPLC. Finally, dau (30% excess) was coupled
to the deprotected aminooxyacetylated peptide, as previously
described, yielding conjugate 3c in satisfactory yield after HPLC
purification (60%).
Solid-Phase Receptor Binding Assay. Human integrin
receptors αvβ3 (R&D Systems, Minneapolis, MN, USA) and
αvβ5 (EMD Millipore Corporation, Inc., Temecula, CA, USA)
were diluted to 0.5 μg/mL in coating buffer containing 20 mM
Tris-HCl (pH 7.4), 150 mMNaCl, 1 mMMnCl2, 2 mM CaCl2,
and 1 mMMgCl2. An aliquot of diluted receptor (100 μL/well)
was added to 96-well microtiter plates (Nunc MaxiSorp, Termo
Fisher Scientific, Roskilde, DK) and incubated overnight at 4 °C.
The plates were incubated with blocking solution (coating
buffer plus 1% bovine serum albumin) for additional 2 h at room
temperature to block nonspecific binding. After washing 2 times
with blocking solution, plates were incubated shaking in the dark
for 3 h at room temperature, with various concentrations (10−5−
10−12 M) of test compounds in the presence of 1 μg/mL
vitronectin (Molecular Innovations, Novi, MI, USA) biotiny-
lated using an EZ-Link Sulfo-NHS-Biotinylation kit (Pierce,
Rockford, IL, USA). After washing 3 times, the plates were
incubated shaking for 1 h in the dark, at room temperature, with
streptavidin−biotinylated peroxidase complex (Amersham
Biosciences, Uppsala, Sweden). After washing 3 times with
blocking solution, plates were incubated with 100 μL/well of
Substrate Reagent Solution (R&D Systems, Minneapolis, MN,
USA) for 30 min shaking in the dark, before stopping the
reaction with the addition of 50 μL/well 2 N H2SO4.
Absorbance at 415 nm was read in a Synergy HT Multi-
Detection Microplate Reader (BioTek Instruments, Inc.). Each
data point represents the average of triplicate wells; data analysis
was carried out by nonlinear regression analysis with GraphPad
Prism software. Each experiment was repeated in duplicate.
Cell Culture. All the cell experiments were carried out under a
laminar flow hood Herasafe. The temperature (37 °C) of the
chemicals used was adjusted by Julabo SW22 heating bath. Cell
culture was carried out at 5% CO2 at 37 °C, using 100 × 20 mm
Bioconjugate Chemistry Article
DOI: 10.1021/acs.bioconjchem.9b00292
Bioconjugate Chem. 2019, 30, 2011−2022
2019
Petri dishes. The medium used for the U87 cells was Dulbecco’s
Modified Eagle’s Medium, high glucose, supplemented with
10% fetal bovine serum (FBS) and 2 mM L-Glutamine and for
the MCF-7 and HT-29 cells RPMI medium (90%) with FBS
(10%) and 2 mM L-glutamine. For cell culturing Dulbecco’s
phosphate buffered saline (PBS 1×) and trypsin-EDTA solution
have been used. All these reagents were obtained from Sigma-
Aldrich (Taufkirchen, Germany). MTT (3-(4,5-dimethylthia-
zol-2-yl)-2,5-diphenyl-tetrazolium bromide) was obtained from
Acros Organics (Geel, Belgium).
Integrin Expression on Cell Surface.Three million cells were
counted for every cell line, then centrifuged in 15 mL tubes at
1,000 rpm for 5 min at 4 °C; afterwards, the supernatant was
removed. To fix the cells, 300 μL of 4% paraformaldehyde was
added to the pellet, which was then resuspended and left 10 min
at rt. Afterward, 2 mL of PBS was added, and the 15 mL tubes
vortexed and centrifuged at 1,000 rpm, 5 min at 4 °C. The
supernatant was discarded and 3 mL PBS was added to the 15
mL tubes. The solution was again resuspended and divided into
3 FACS tubes (one as control and two for the treatment with
antibody). The antibody used was an anti-integrin αvβ3 Ab clone
LM609 purchased fromMerckMillipore. After addition of 2 mL
of PBS to each tube, centrifugation followed with the same
conditions as before and supernatant was removed. 50 μL of 3%
BSA in PBS was added to each tube to block nonspecific binding
sites. The solution was left for 10 min at rt and moved from time
to time. After this blocking step, 50 μL of antibody mixture
(dilution 1:25; 2 μL antibody, 23 μL PBS, and 25 μL 3% BSA)
were added to each FACS tube, incubated for 60 min at 37 °C,
and moved from time to time. After this incubation time, cells
were washed by adding 2 mL of PBS. Centrifugation was
performed, the supernatant removed, and the pellet was then
dissolved in FACSmedium to proceed with the quantification of
the fluorescence intensity.
MTT Cytotoxicity Assay. To investigate the antiproliferative
activity of the conjugates on the human tumor cell lines U87,
HT-29 and MCF-7, a MTT assay was performed. Cells were
seeded in a 96-well plate purchased from Greiner Bio-One
(Frickenhausen, Germany) (6,000 cells per well), grown for 24
h, and incubated with various concentrations of the conjugate in
appropriate serum-containing medium for 72 h or 15 min,
followed by medium removal, and incubation with fresh
medium for additional 72 h under standard growth conditions.
The MTT assay was performed by adding 20 μL of MTT
solution (5 mg mL−1 in PBS) to each well and after 3 h of
incubation at 37 °C, the supernatant was removed. The
formazan crystals were dissolved in 100 μL of a 1:1 solution of
DMSO and EtOH and the absorbance was determined at 570
nm with a microplate reader (BIO-RAD, model 550).
Background value (absorbance of DMSO−EtOH) was
subtracted from the measured values and the percentage
decrease in cell proliferation was determined relatively to
untreated cells.
Quantification of Cellular Uptake and Competition/
Blocking Experiment by Flow Cytometry. For uptake studies
by flow cytometry, cells were seeded in a 24-well plate (U87:
150,000 cells per well; HT-29 and MCF-7:120,000 cells per
well) and grown to 70−80% confluency. After incubation at 37
°C for 15, 30, or 60 min with the labeled peptides (CF or
daunorubicin) in serum-free medium, the cells were washed
twice with PBS, detached with indicator-free trypsin and
resuspended in indicator-free serum containing-RPMI medium.
The cell suspension was moved into a 96-well FACS plate and
the fluorescence was then measured by a Guava easyCyte flow
cytometer (Merck) where 10,000 viable cells were counted.
Cellular autofluorescence was subtracted. The experiments were
performed twice in triplicates. For competition experiment the
unfunctionalized c[DKP-RGD] ligand was added in 10-fold
excess together with the peptide. After 30 or 60 min incubation
time the medium was removed and the cells were treated as
described above. For blocking experiments, the cells were
preincubated with c[DKP-RGD] (10 μM), poly(L-lysine) or
methyl-β-cyclodextrin (1 mM) for 30 min and then treated with
the peptide for 30 min.
Microscopy Studies for Cellular Uptake. For confocal
microscopy uptake studies, cells were seeded in an eight-well
(Ibidi) plate (U87:70,000 cells per well; HT-29 and MCF-
7:50,000 cells per well), and grown to 70−80% confluency. The
cells were then incubated with CF- or daunorubicin-labeled
peptides in serum-free medium for 30 min at 37 °C. The nuclei
were stained for 10 min with Hoechst 33342 nuclear dye
(bisbenzimide H33342, 1 mg/mL in H2O, sterile filtered) prior
to the end of peptide incubation. Finally, the solution was
removed and cells were treated with 200 μL trypan blue solution
(150 mm in 0.1 M acetate buffer, pH 4.15) for 15 s. After
washing once with serum-free medium and adding fresh,
appropriate serum-containing medium, images were taken by
using a Leica SP8 confocal laser scanning microscope equipped
with a 60 V oil-immersion objective. Images were recorded with
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the version published on July 17, 2019.
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